Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLMNASDAQ:GTBPNASDAQ:MYNZNASDAQ:SHPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMApollomics$6.44-6.9%$6.12$4.47▼$35.98$7.10M0.999,939 shs3,936 shsGTBPGT Biopharma$2.84+0.7%$2.47$1.72▼$4.10$7.34M1.37246,073 shs67,834 shsMYNZMainz Biomed$1.83-8.0%$2.62$1.80▼$25.60$6.30M0.31132,271 shs115,689 shsSHPHShuttle Pharmaceuticals$0.13-9.4%$6.10$0.12▼$4.30$1.46M-1.11.82 million shs3.99 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMApollomics0.00%-1.90%+39.09%-14.20%-70.86%GTBPGT Biopharma0.00%+5.97%+26.79%+10.94%-4.70%MYNZMainz Biomed0.00%-11.81%-19.38%-58.03%-93.11%SHPHShuttle Pharmaceuticals-96.00%-97.10%-97.61%-98.56%+13,279,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLMApollomics1.2333 of 5 stars0.05.00.00.03.30.00.6GTBPGT Biopharma2.6397 of 5 stars3.82.00.00.02.40.81.3MYNZMainz Biomed2.6013 of 5 stars3.35.00.00.00.70.81.3SHPHShuttle Pharmaceuticals0.804 of 5 stars0.04.00.00.02.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLMApollomics 0.00N/AN/AN/AGTBPGT Biopharma 3.50Strong Buy$11.00287.32% UpsideMYNZMainz Biomed 2.50Moderate Buy$14.00665.03% UpsideSHPHShuttle Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLMApollomics$1.22M5.82N/AN/A$47.51 per share0.14GTBPGT BiopharmaN/AN/AN/AN/A$5.42 per shareN/AMYNZMainz Biomed$893.99K7.04N/AN/A$10.82 per share0.17SHPHShuttle PharmaceuticalsN/AN/AN/AN/A$2.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLMApollomics-$172.60MN/A0.00∞N/AN/AN/AN/AN/AGTBPGT Biopharma-$7.60M-$5.69N/AN/AN/AN/A-257.47%-131.09%8/13/2025 (Estimated)MYNZMainz Biomed-$26.30M-$65.60N/AN/AN/AN/AN/AN/A7/1/2025 (Estimated)SHPHShuttle Pharmaceuticals-$6.59M-$4.15N/A∞N/AN/A-583.02%-258.92%N/ALatest SHPH, APLM, GTBP, and MYNZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/1/2025N/AMYNZMainz Biomed-$2.80N/AN/AN/AN/AN/A5/15/2025Q1 2025GTBPGT Biopharma-$0.64-$0.76-$0.12-$0.33N/AN/A5/8/2025Q1 2025SHPHShuttle PharmaceuticalsN/A-$7.50N/A-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLMApollomicsN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLMApollomicsN/A2.25N/AGTBPGT BiopharmaN/A1.451.45MYNZMainz BiomedN/A0.240.19SHPHShuttle PharmaceuticalsN/A0.220.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLMApollomics19.13%GTBPGT Biopharma8.15%MYNZMainz BiomedN/ASHPHShuttle Pharmaceuticals4.58%Insider OwnershipCompanyInsider OwnershipAPLMApollomicsN/AGTBPGT Biopharma10.90%MYNZMainz Biomed18.20%SHPHShuttle Pharmaceuticals12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLMApollomics451.10 millionN/ANot OptionableGTBPGT Biopharma82.59 million1.99 millionNo DataMYNZMainz Biomed303.44 million1.64 millionNot OptionableSHPHShuttle Pharmaceuticals510.98 million2.46 millionNot OptionableSHPH, APLM, GTBP, and MYNZ HeadlinesRecent News About These CompaniesShuttle Pharmaceuticals Holdings Inc trading halted, news pendingJune 14 at 11:42 AM | msn.comShuttle Pharmaceuticals says reverse stock split to become effective June 16June 13 at 3:10 PM | finance.yahoo.comShuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern TimeJune 12 at 12:00 PM | globenewswire.comShuttle Pharmaceuticals Holdings, Inc. Proposes 25-for-1 Reverse Stock Split to Comply with Nasdaq RequirementsJune 12 at 8:56 AM | quiverquant.comShuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance InitiativeJune 12 at 8:30 AM | globenewswire.comShuttle Pharma Appoints George Scorsis Chairman of the Board of DirectorsJune 4, 2025 | globenewswire.comShuttle Pharmaceuticals slashes exec salaries by 70% as it fights to preserve cashMay 29, 2025 | bizjournals.comShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deShuttle Pharma Provides Corporate UpdateMay 15, 2025 | globenewswire.comShuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical TrialMay 8, 2025 | globenewswire.comShuttle Pharmaceuticals to Present Phase 2 Trial Update at Planet MicroCap Showcase: VEGAS 2025April 24, 2025 | nasdaq.comShuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025April 21, 2025 | globenewswire.comShuttle Pharmaceuticals files provisional patent application with USPTOApril 12, 2025 | markets.businessinsider.comShuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate CancerApril 10, 2025 | globenewswire.comShuttle Pharmaceuticals Appoints New Interim CEO and CSOMarch 31, 2025 | tipranks.comShuttle Pharmaceuticals Holdings, Inc. Closes $5.75 Million Public Offering to Fund Phase II Clinical TrialMarch 13, 2025 | quiverquant.comShuttle Pharma Announces Closing of $5.75 Million Underwritten OfferingMarch 13, 2025 | globenewswire.comShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business ActivitiesMarch 12, 2025 | finanznachrichten.deShuttle Pharmaceuticals appoints Christopher Cooper as interim Co-CEOMarch 12, 2025 | markets.businessinsider.comShuttle Pharmaceuticals prices 19.17M shares at 30c per share in public offeringMarch 12, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSHPH, APLM, GTBP, and MYNZ Company DescriptionsApollomics NASDAQ:APLM$6.44 -0.48 (-6.94%) Closing price 06/13/2025 03:58 PM EasternExtended Trading$6.50 +0.06 (+0.92%) As of 06/13/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.GT Biopharma NASDAQ:GTBP$2.84 +0.02 (+0.71%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.80 -0.04 (-1.41%) As of 06/13/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.Mainz Biomed NASDAQ:MYNZ$1.83 -0.16 (-8.04%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.84 +0.01 (+0.77%) As of 06/13/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.Shuttle Pharmaceuticals NASDAQ:SHPH$0.13 -0.01 (-9.35%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.13 0.00 (-1.36%) As of 06/13/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
